OPRM1 and CYP3A4 association with methadone dose in Iranian patients undergoing methadone maintenance therapy

References

• Zou Z, Wang H, Uquillas FdO, Wang X, Ding J, Chen H. Definition of substance and non-substance addiction. Advances in Experimental Medicine and Biology; 2017;1010:21–41. doi:10.1007/978-981-10-5562-1_2
   Google Scholar
• Merikangas KR, McClair VL. Epidemiology of substance use disorders. Hum Genet. 2012;131(6):779–89. doi:10.1007/s00439-012-1168-0.
   PubMed Web of Science ®Google Scholar
• Shahbazi F, Mirtorabi SD, Ghadirzadeh MR, Hashemi-Nazari SS, Barzegar A. Characterizing mortality from substance abuse in Iran: an epidemiological study during March 2014 to February 2015. Addict Health. 2017;9(3):166–74.
   PubMedGoogle Scholar
• Saloner B, Karthikeyan S. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013. JAMA. 2015;314(14):1515–7. doi:10.1001/jama.2015.10345.
   PubMed Web of Science ®Google Scholar
• Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45–50. doi:10.4103/0976-3147.91934.
   PubMedGoogle Scholar
• Tenegra JC, Leebold B. Substance abuse screening and treatment. Prim Care. 2016;43(2):217–27. doi:10.1016/j.pop.2016.01.008.
   PubMed Web of Science ®Google Scholar
• Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357–68. doi:10.1056/NEJMra1604339.
   PubMed Web of Science ®Google Scholar
• Fonseca F, Gratacòs M, Escaramís G, De Cid R, Martín-Santos R, Fernández-Espejo E, Estivill X, Torrens M. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171–8. doi:10.1007/BF03256370.
   PubMed Web of Science ®Google Scholar
• Hung C-C, Chiou M-H, Huang B-H, Hsieh Y-W, Hsieh T-J, Huang C-L, Lane H-Y. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011;12(11):1525–33. doi:10.2217/pgs.11.96.
   PubMed Web of Science ®Google Scholar
• Stein C. Opioid receptors. Annu Rev Med. 2016;67:433–51. doi:10.1146/annurev-med-062613-093100.
   PubMed Web of Science ®Google Scholar
• Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, Ferraro TN, Hakonarson H, Kampman KM, Dackis CA, et al. Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2013;127(1–3):122–8. doi:10.1016/j.drugalcdep.2012.06.023.
   PubMed Web of Science ®Google Scholar
• Crettol S, Déglon J-J, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6):668–81. doi:10.1016/j.clpt.2006.09.012.
   PubMed Web of Science ®Google Scholar
• Richards-Waugh LL, Primerano DA, Dementieva Y, Kraner JC, Rankin GO. Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism. J Anal Toxicol. 2014;38(8):541–7. doi:10.1093/jat/bku091.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76(3):250–69. doi:10.1016/j.clpt.2004.05.003.
   PubMed Web of Science ®Google Scholar
• Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004;26(2):192–9. doi:10.1097/00007691-200404000-00019.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. JNCI: J Natl Cancer Inst. 1998;90(16):1225–9. doi:10.1093/jnci/90.16.1225.
   Web of Science ®Google Scholar
• Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics and Genomics. 2002;12(2):121–32.
   Google Scholar
• Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G, Liddle C. TheCYP3A4* 1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics and Genomics. 2002;12(5):355–66.
   Google Scholar
• Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013;14(7):813–24. doi:10.2217/pgs.13.57.
   PubMed Web of Science ®Google Scholar
• Breen K. (n.d.). Part B: 20 Questions and Answers Regarding Methadone Maintenance Treatment Research. NIDA International Program. https://www.drugabuse.gov/sites/default/files/pdf/partb.pdf
   Google Scholar
• Li Y, Kantelip J-P, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12(2):109–24. doi:10.1007/BF03256276.
   PubMed Web of Science ®Google Scholar
• Levran O, Peles E, Randesi M, Shu X, Ott J, Shen P-H, Adelson M, Kreek MJ. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013;14(7):755–68. doi:10.2217/pgs.13.58.
   PubMed Web of Science ®Google Scholar
• Wang S-C, Tsou H-H, Chen C-H, Chen Y-T, Ho I-K, Hsiao C-F, Chou S-Y, Lin Y-F, Fang K-C, Huang C-L, et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur Neuropsychopharmacol. 2012;22(10):695–703. doi:10.1016/j.euroneuro.2012.02.002.
   PubMed Web of Science ®Google Scholar
• Bauer IE, Soares JC, Nielsen DA. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: a systematic review. Am J Addict. 2015;24(1):15–23. doi:10.1111/ajad.12172.
   PubMed Web of Science ®Google Scholar
• Crettol S, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Déglon J-J, Preisig M, Eap CB. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1722–7. doi:10.1016/j.pnpbp.2008.07.009.
   PubMed Web of Science ®Google Scholar
• Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJ, Somogyi AA. ABCB1 haplotype and OPRM1 118A> G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and personalized medicine. 2012;5:53.
   Google Scholar
• Fattahi Z, Beheshtian M, Mohseni M, Poustchi H, Sellars E, Nezhadi SH, Amini A, Arzhangi S, Jalalvand K, Jamali P, et al. Iranome: a catalogue of genomic variations in the Iranian population. Hum Mutat. 2019;40(11):1968–17. doi:10.1002/humu.23880.
   PubMed Web of Science ®Google Scholar